InvestorsHub Logo

flipper44

12/08/18 12:08 PM

#202593 RE: AVII77 #202592

Uh, Advent have been making DCVax-L in London and are migrating all their facilities to Sawston AVII. Fiddle away.

AVII77

12/08/18 12:38 PM

#202596 RE: AVII77 #202592

That's just deflection flipper.

Do they make DCVax from donor organs?

Here's the master plan Flipper.

xoma4578

12/08/18 12:41 PM

#202598 RE: AVII77 #202592

AVII - can you explain in plan English on your post? Or anyone? Flipper, Doc logic, Senti.

BTW - added few more shares this week from 2018 Xmas bonus just received.

Long with just under 1.5M shares.

TopelRoad

12/08/18 12:54 PM

#202603 RE: AVII77 #202592

I think your highlighted paragraph is about DCVax-D.
Apparently DCVax-D can be semi allogeneic, that is a big deal patient and money wise. Very good news for longs.

longfellow95

12/08/18 12:56 PM

#202604 RE: AVII77 #202592

How much umbilical cord blood does it take to make a dose of DCvax?



I think you are getting your technologies mixed up.

AV. Barrel and scrape comes to mind.

By the way this was part of a planning application, and it wouldn't be LP if she didn't obscure things somewhat with a little smokescreen.

It comes with the territory I'm afraid.


LP's idiosyncratic way of operating is what it is. If that is of sufficient concern to a potential shareholder, then they should keep their money in their pocket.

TopelRoad

12/08/18 12:59 PM

#202605 RE: AVII77 #202592

Scaffold? Is that about taking organs not suitable for transplantation and repairing them with stem cells? That is a good idea, I did not know they were working on that?

Could you send the link to this document?

Lykiri

12/08/18 2:45 PM

#202614 RE: AVII77 #202592

How much umbilical cord blood does it take to make a dose of DCvax?

Looks like even in 2014 they didn't plan on using Sawston for DCVax.



On December 9, 2014, Aracaris Capital Ltd, a subsidiary of the Company in the UK, completed the purchase of the second portion of the property intended for the manufacturing expansion for DCVax products in the UK. This property is located within and surrounded by the first portion of the property already acquired by Aracaris, as previously reported. The purchase price for the additional property was £5 million (approximately $7.86 million). The additional property includes approximately 12 acres of potentially developable land (as well as non-developable land), and certain existing buildings. Development of the property for DCVax manufacturing will require approval by the Planning Commission to re-classify the property, removal of certain existing structures, making certain site improvements, Planning Commission approval of the intended use after re-classification, and Planning Commission approval of the specific designs and engineering. The Company plans to explore various structures and approaches for financing and/or development of the property that may enable the Company to withdraw its capital from the property.
https://www.sec.gov/Archives/edgar/data/1072379/000114420414073984/v396605_8k.htm

Lykiri

12/09/18 11:18 AM

#202678 RE: AVII77 #202592


NWBO investors are being played like a fiddle.AVII77



Aracaris Capital Limited
The Vision Centre
Former Spicers Site Mill Lane Sawston Cambridge

PROPOSED CHANGE OF USE FROM B8 TO B2 USE TO CREATE ADVANCED THERAPY MEDICINE MANUFACTURING FACILITY

TRANSPORT STATEMENT VOLUME 1 of 2 TEXT FIGURES AND TABLES
Technical Report 56000/2 August 2014

Mark Baker
Consulting Limited
Bristol.

3.6 Movement Generation: First Principles

3.6.1 The proposal is a particular specialised type of manufacturing, and hence it is appropriate to consider the assessment of movement generation based on a first principles assessment.

3.6.2 The site is proposed to be operated by a contract manufacturer of medicines, but whilst most conventional drugs are manufactured from their constituent chemicals, the medicines produced are manufactured from human cells, and typically from the patients themselves. The medicines produced are “cutting edge”, and are part of a new class of medicines called Advanced Therapy Medicines.

3.6.3 Every medicine produced at the site will originate from human donor cells, and / or tissues. These will derive either from the patient, or a close relative, but there may be some from a bank of cells made specifically for one type of product including for example stem cell bank from donated umbilical cord blood. Another starting material is organs from the NHS Blood and Transplant Service that is unsuitable for routine transplantation but can be used as a “scaffold” for product development. Such products will be harvested across the UK, and transported to Sawston by specialised courier service.

3.6.4 The work that will be involved in the production of such medicines is undertaken on a small scale across the UK in major hospital, but this facilities would be the first “large scale” manufacturing facility. That said the work at the site is largely similar to that seen at Blood Transfusion Centres with the predominant traffic generation being by car for staff, and any professional visitors, and by the unit’s own vehicles for goods in and out for the most part.

3.6.5 It is anticipated that when fully operational, and in full occupation the site will employ the following levels of staff by skill type, and shift:
i) Manufacturing staff would work on two shifts from Monday to Saturday 07.30 – 16.30 25 staff 15.00 – 23.00 25 staff
ii) Warehouse staff would also work on two shifts from Monday to Saturday 07.30 – 16.30 4 staff 15.00 – 23.00 4 staff
iii) Site security staff on three shifts 07.30 – 16.30 1 staff 15.00 – 23.00 1 staff
iv) 5 scientists for product development on Monday to Friday 09.00 – 17.30
v) 5 office / support staff on Monday to Friday 09.00 – 17.30

3.6.6 Table 3 shows the arrival / departure profiles based on a first principles assessment. The arrival / departure profile assumes that staff will arrive and depart within the quarter of an hour before and after their shift start respectively. As a “worst case” assessment, the profiles assume the following modal split:
Car 94%
Cycle 4%
Walk including public transport 2%
These values are from the Sawston Business Park TA. There were no values provided for by public transport access which are taken as being included within the walk percentages.

3.6.7 The profile also indicates an assessment of parking accumulation which indicates that between 14.45 and 16.45 that there may be a need to accommodate the parking demand of two shifts of 65 vehicles in total. The overall car parking provision including the main car park would be adequate to accommodate the demand by staff, and visitors.

3.6.8 In addition to the staff movements, there are likely to be regular, and irregular goods vehicle movements as follows:
Delivery and pick up 20 per day by transit sized vehicle
Delivery by box van 12 per week
Cryogenic delivery trucks 2 per week (once every 3 days)
Domestic refuse removal 1 per week
Clinical waste removal by box van 3 per week

3.7 Traffic Distribution

3.7.1 The vehicular traffic distribution used for testing purposes if appropriate will be identical to that of the TA prepared for the Sawston Business Park planning application for cars, and goods vehicles as follows:
Cars HGVs
a) To / from Whittlesford Road 20% 0%
b) To / from A1301 then
To / from the north 20% 33%
To / from Sawston 20% 0%
To / from south 40% 67%